Who is buying Mirati?

Who exactly is driving the surge in interest and investment in Mirati Therapeutics? Are we seeing institutional investors taking a larger stake, or is it retail traders piling on? Could it be a combination of both? Additionally, what specific factors or developments have contributed to the increase in demand for Mirati's shares? Is it a promising drug pipeline, positive clinical trial results, or perhaps a strategic partnership that has captured investors' attention? Understanding the motivations and demographics of those buying Mirati is crucial to gaining a deeper insight into its potential future performance.